Inhibitors Clinical Trials

70 recruitingLast updated: July 25, 2026

There are 70 actively recruiting inhibitors clinical trials across 43 countries. Studies span Not Applicable, Phase 2, Phase 4, Phase 3, Phase 1. Top locations include Guangzhou, Guangdong, China, Tianjin, Tianjin Municipality, China, Changsha, Hunan, China. Updated daily from ClinicalTrials.gov.


Inhibitors Trials at a Glance

70 actively recruiting trials for inhibitors are listed on ClinicalTrialsFinder across 6 cities in 43 countries. The largest study group is Not Applicable with 16 trials, with the heaviest enrollment activity in Guangzhou, Tianjin, and Changsha. Lead sponsors running inhibitors studies include Kong Fanming, Second Xiangya Hospital of Central South University, and Second Affiliated Hospital, School of Medicine, Zhejiang University.

Browse inhibitors trials by phase

Treatments under study

About Inhibitors Clinical Trials

Looking for clinical trials for Inhibitors? There are currently 2 studies actively recruiting participants. Clinical trials offer access to new treatments before they are widely available, and every approved therapy in use today was first tested through a clinical trial.

Below you can browse trials, sign up for alerts when new Inhibitors trials open, and view eligibility criteria for each study. Each listing includes the study phase, locations, and enrollment details.

Frequently Asked Questions

Common questions about Inhibitors clinical trials

A clinical trial is a carefully designed research study that tests new medical treatments, drugs, devices, or approaches in human volunteers. Every approved medication and treatment available today was proven safe and effective through clinical trials.

All clinical trials are reviewed and approved by Institutional Review Boards (IRBs) — independent committees that evaluate patient safety. Trials follow strict protocols, and your health is monitored closely throughout. You can withdraw at any time.

Not necessarily. Many trials compare the new treatment against the current standard of care, meaning all participants receive active treatment. When placebos are used, they are typically combined with standard treatment, not given alone. The trial description will always specify the design.

Under the Affordable Care Act, most private insurers are required to cover routine patient care costs during a clinical trial. The sponsor typically covers the investigational treatment itself. Medicare also covers routine costs for qualifying trials.

Yes. Participation is completely voluntary. You can withdraw at any time, for any reason, without it affecting your access to standard medical care.

Each trial has specific eligibility criteria — including age, diagnosis, disease stage, prior treatments, and general health. Browse the trials listed above and check their eligibility sections. You can also contact the trial site directly to discuss your situation.

Showing 120 of 70 trials

Recruiting
Phase 2

Early Metabolic Effects of Antiretroviral Drugs in Healthy volUnteers: a Phase 2 Randomized Study

Weight GainHealthy VolunteerMetabolic Effects+1 more
National Institute of Allergy and Infectious Diseases (NIAID)120 enrolled1 locationNCT05652478
Recruiting
Not Applicable

DETERMINANTS OF IMMUNOTHERAPY EFFICACY IN ENDOMETRIAL CANCER

Endometrial CancerImmune Checkpoint Inhibitors
European Institute of Oncology510 enrolled1 locationNCT07690540
Recruiting
Phase 3

A Research Study Looking at Long-term Treatment With Mim8 in People With Haemophilia A

Haemophilia AHaemophilia A With Inhibitors
Novo Nordisk A/S451 enrolled152 locationsNCT05685238
Recruiting
Not Applicable

Electro-Acupuncture in Lung cancER : EALER Study

Non-small Cell Lung CancerPD-1 InhibitorsAccupuncture
Guangzhou University of Traditional Chinese Medicine424 enrolled3 locationsNCT07337096
Recruiting

Prospective Cohort of Immune Checkpoint Inhibitor-induced Hepatitis

Cancer PatientsLiver InjurySecondary to Immune Checkpoint Inhibitors
University Hospital, Montpellier250 enrolled1 locationNCT06864481
Recruiting
Phase 3

Perioperative Durvalumab With Neoadjuvant ddMVAC or Gemcitabine/Cisplatin in Patients With Muscle-invasive Bladder Cancer (NIAGARA-2)

Urinary Bladder NeoplasmsImmune Checkpoint InhibitorsMethotrexate+4 more
AstraZeneca150 enrolled59 locationsNCT06960577
Recruiting
Phase 3

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in Europe (PLATINUM EU)

Molecular Mechanisms of Pharmacological ActionPeripheral Nervous System AgentsNeurotransmitter Agents+7 more
Merz Aesthetics GmbH300 enrolled26 locationsNCT07210463
Recruiting
Phase 4

AntiPlatelet theraPy stratEgy followiNg Left Atrial appenDAGe closurE

Atrial FibrillationStrokePlatelet Aggregation Inhibitors+2 more
University Hospital, Bordeaux60 enrolled2 locationsNCT04796714
Recruiting

Mechanism of Enhanced Efficacy of Ivonescimab in Neoadjuvant Therapy for Non-Small Cell Lung Cancer

Neoadjuvant TherapyNon-small Cell Lung CancerImmunotherapy+1 more
Peking University People's Hospital80 enrolled1 locationNCT07359040
Recruiting
Not Applicable

Personalizing Thromboprophylaxis for Patients With Peripheral Artery Disease

ThrombosisAmputationPlatelet Aggregation Inhibitors+4 more
Massachusetts General Hospital484 enrolled2 locationsNCT07613840
Recruiting
Not Applicable

Dental Implant Healing With TNF-Alpha Inhibitors

Dental ImplantsEdentulismTNF-alpha Inhibitors
University of Pennsylvania30 enrolled1 locationNCT06538870
Recruiting
Not Applicable

Deprescribing Inappropriate Proton Pump Inhibitors

inappropriate prescribingProton Pump InhibitorsReflux Disease
University of Bern400 enrolled2 locationsNCT06129474
Recruiting
Phase 3

meChANisms and sAfety of SGLT2 Inhibition in peRitoneal dialYsis

Kidney DysfunctionEnd-stage Kidney DiseasePeritoneal Dialysis Complication+2 more
University Health Network, Toronto20 enrolled1 locationNCT05715814
Recruiting

Development and Application of a Thrombosis Risk Prediction Model in Lung Cancer Patients Treated With Immune Checkpoint Inhibitors

Lung CancerVenous ThromboembolismArterial Thromboembolism+1 more
Beijing Chao Yang Hospital2,400 enrolled5 locationsNCT06950697
Recruiting

A Real-world Study on the Efficacy and Safety of Menin Inhibitors as Maintenance After Allo-HSCT

Acute LeukemiaMenin InhibitorsPost Hematopoietic Stem Cell Transplantation+4 more
The First Affiliated Hospital of Soochow University20 enrolled1 locationNCT07559695
Recruiting
Phase 4

Efficacy and Safety of Sodium-Glucose Cotransporter-2 Inhibitors in Adolescents With Early Stages of Chronic Kidney Disease

AdolescentAlbuminuriaSodium-glucose Co-transporter-2 Inhibitors+1 more
Centenario Hospital Miguel Hidalgo200 enrolled1 locationNCT07405216
Recruiting
Phase 2

Efficacy and Safety of Serplulimab Combined With Chemotherapy as Neoadjuvant Treatment for Locally Advanced Gastric Cancer or Adenocarcinoma of Esophagogastric Junction

Stomach NeoplasmsImmune Checkpoint Inhibitors
Xijing Hospital116 enrolled5 locationsNCT06576921
Recruiting

A Qualitative Assessment of the Severity and Impact of Rheumatic Immune-Related Adverse Events Following Immune Checkpoint Inhibitor Immunotherapy

Immune Checkpoint InhibitorsArthritisPolymyalgia Rheumatica
M.D. Anderson Cancer Center20 enrolled1 locationNCT06647134
Recruiting
Phase 3

A Study of NT 201 in Adults With Moderate to Severe Platysma Prominence in the United States

Molecular Mechanisms of Pharmacological ActionPeripheral Nervous System AgentsNeurotransmitter Agents+7 more
Merz North America, Inc.300 enrolled28 locationsNCT07122193
Recruiting

Observational Cohort Study of Chronic Viral Infection in the Central Nervous System

Immune Checkpoint InhibitorsProgressive Multifocal Leukoencephalopathy
Peking Union Medical College Hospital66 enrolled1 locationNCT07512518